How Cigna’s AI chief is investing in the technology to cut costs and address some of health care’s biggest problems

When Katya Andresen stepped into her role as chief data, digital and AI officer at Cigna Group in 2021, she found an industry obsessed with a single question: how do we use AI? For Andresen, that approach was too narrow. Instead of simply chasing various tools or functions, she shifted the internal conversation toward how the company could lead in an age of artificial intelligence. Her goal is to move beyond novelty and focus on measurable investments that actually improve health outcomes while trimming the fat from one of the world’s most expensive industries.

The financial stakes are immense, with national healthcare spending now exceeding five trillion dollars annually. To combat these rising costs, Cigna is deploying predictive analytics to catch chronic conditions like cancer and kidney disease early. The company estimates that proactively connecting high risk patients with clinicians could save two hundred million dollars over the next three years. Beyond patient care, Cigna is investing another hundred million dollars through 2028 to automate clinician documentation and streamline prescriptions, reducing the administrative burden that often leads to physician burnout.

One of the most tangible successes of this strategy involves biosimilars, which are lower cost alternatives to expensive biologic drugs. By analyzing thousands of customer conversations via AI, Cigna identified exactly why patients were hesitant to switch from brand name medications like Humira, which can cost seven thousand dollars a month. By refining their digital messaging based on these insights, Cigna convinced more than eighty percent of targeted patients to make the switch, saving patients hundreds of millions of dollars and increasing margins for the company.

Despite these wins, the integration of AI into healthcare brings significant risks regarding patient privacy and accuracy. With more people turning to chatbots for medical advice rather than visiting doctors, the need for strict guardrails is paramount. Andresen argues that because Cigna operates in a highly regulated environment, they already possess a foundation of compliance and governance that newer tech firms lack. She believes the future of medicine lies in conversational and proactive AI that offers true personalization rather than just basic navigation through a complex system.

To achieve this vision, Andresen is blending proprietary data with partnerships involving giants like OpenAI and Anthropic, alongside specialized startups such as Sierra. From summarizing millions of call center interactions to creating virtual assistants within the mobile app, Cigna is attempting to turn vast amounts of raw data into actionable precision medicine. Having navigated her own family’s recent struggle with a breast cancer diagnosis, Andresen views these technological advancements not just as corporate efficiencies but as essential tools for making a fragmented system feel human again.